Evidence map›Paper›PMID 36304303›Full record

ArticleFrontiers in bioinformatics2022

Prediction of Adverse Drug Reaction Linked to Protein Targets Using Network-Based Information and Machine Learning.

Cristiano Galletti, Joaquim Aguirre-Plans, Baldo Oliva, Narcis Fernandez-Fuentes

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Cristiano GallettiDepartment of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain.
Joaquim Aguirre-PlansDepartment of Physics, Network Science Institute, Northeastern University, Boston, MA, United States.
Baldo OlivaDepartment of Experimental and Health Sciences, Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.
Narcis Fernandez-FuentesDepartment of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain.
Universitat de Vic - Universitat Central de Catalunya · ESNortheastern University · USPompeu Fabra University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug discovery attrition rates, particularly at advanced clinical trial stages, are high because of unexpected adverse drug reactions (ADR) elicited by novel drug candidates. Predicting undesirable ADRs produced by the modulation of certain protein targets would contribute to developing safer drugs, thereby reducing economic losses associated with high attrition rates. As opposed to the more traditional drug-centric approach, we propose a target-centric approach to predict associations between protein targets and ADRs. The implementation of the predictor is based on a machine learning classifier that integrates a set of eight independent network-based features. These include a network diffusion-based score, identification of protein modules based on network clustering algorithms, functional similarity among proteins, network distance to proteins that are part of safety panels used in preclinical drug development, set of network descriptors in the form of degree and betweenness centrality measurements, and conservation. This diverse set of descriptors were used to generate predictors based on different machine learning classifiers ranging from specific models for individual ADR to higher levels of abstraction as per MEDDRA hierarchy such as

Indexed as

drug adverse reactiondrug targetmachine learningnetwork biologyprotein-adverse reaction association

Identifiers

PMID36304303
PMCPMC9580901
OpenAlexW4285494123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.